X

Trial Profile

A real word study of Etanercept Biosimilar GP 2015 (Erelzi) in rheumatoid arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
Focus Therapeutic Use
Acronyms COMPACT

Most Recent Events

15 Nov 2023 Results assessing drug persistence of GP2015 in patients with RA after 12 months, presented at the ACR Convergence 2023.
03 Jun 2023 Results assessing patient usage behaviour and feelings of self-administered injection from patients in Germany and UK who initiated treatment with GP2015 presented at the 24th Annual Congress of the European League Against Rheumatism
14 Nov 2022 Results presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com